DR-0201, a CD20-directed bispecific antibody, has demonstrated robust B-cell depletion in early clinical studies, showing ...

Under the terms of the deal, Sanofi will pay $600 million upfront to buy an affiliate of the California-based biotech, called ...

Cytokinetics has a strong cash runway but faces risks from its Royalty Pharma deal. Read more on what's ahead for this ...

Sanofi plans to begin shipping flu vaccines ... that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the ...

Sanofi India announced that its Board of Directors has approved of the company selling its commercial premises, being five floors and corresponding car-parking spaces in the building known as ...

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant ...

In a move to expand its portfolio beyond antibiotics, Paratek Pharmaceuticals has bought out Optinose and its chronic ...

Campus Sanofi is a practical example of a commercial healthcare company going out of its way, investing in a long-term programme addressing real needs of doctors and developing trust through ...

Amicus Therapeutics benefits from strong revenue and limited competition. Learn why FOLD stock is a BUY, with a favorable ...

VCG. Shanghai is set to host a global investment promotion conference next week, bringing together hundreds of industry ...

The government has identified life sciences as one of the sectors with the highest potential for growth in the UK and plans to make it a key pillar of its upcoming industry strategy. The ...